The pharmaceutical industry is calling for improvements as their drugs that have completed bioequivalence tests per the government’s insurance price ceiling reevaluations may face larger price cuts under ‘Type C’ of the Price Volume Agreement negotiations this year.

Generic drugs that have completed bioequivalence tests during the insurance price ceiling reevaluations have maintained their existing prices. On the other hand, the price of a number of drugs that were unable to demonstrate bioequivalence was cut, leveling the weighted average price of the same ingredient drugs (substitutes) downward. The higher the price of the drug in negotiations as compared to the weighted average price of